Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs

Journal of Diabetes and its Complications

Volumn 31, Issue 3, 2017, Pages 521-522

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMBINATION DRUG THERAPY; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; NON-ALCOHOLIC FATTY LIVER DISEASE; SITAGLIPTIN PHOSPHATE;

EID: 85008449832     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.12.006     Document Type: Editorial

References (20)

1. Armstrong, M.J., Gaunt, P., Aithal, G.P., Newsome, P.N., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:10019 (2016), 679–690.
2. Athyros, V.G., Katsiki, N., Karagiannis, A., Editorial: Can glucagon like peptide 1 (GLP1) agonists or sodium-glucose Co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes?. Current Vascular Pharmacology 14:6 (2016), 494–497.
3. Athyros, V.G., Katsiki, N., Mikhailidis, D.P., Editorial: Resolution of non-alcoholic-steatohepatitis. More than one drug needed?. Current Vascular Pharmacology 14:4 (2016), 313–315.
4. Athyros, V.G., Tziomalos, K., Katsiki, N., Doumas, M., Karagiannis, A., Mikhailidis, D.P., Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 21:22 (2015), 6820–6834.
5. Carbone, L.J., Angus, P.W., Yeomans, N.D., Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology 31:1 (2016), 23–31.
6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:6 (2016), 1121–1140.
7. Guo, K., Zhang, L., Lu, J., Yu, H., Wu, M., Bao, Y.,.. Jia, W., Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. Journal of Diabetes and its Complications 31:1 (2017), 80–85.
8. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): A relationship with implications for vascular risk?. Current Vascular Pharmacology 9:6 (2011), 698–705.
9. Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., The role of statins in the treatment of type 2 diabetes mellitus: An update. Current Pharmaceutical Design 20:22 (2014), 3665–3674.
10. Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 65:8 (2016), 1109–1123.
11. Katsiki, N., Papanas, N., Fonseca, V.A., Maltezos, E., Mikhailidis, D.P., Uric acid and diabetes: Is there a link?. Current Pharmaceutical Design 19:27 (2013), 4930–4937.
12. Lonardo, A., Ballestri, S., Guaraldi, G., Nascimbeni, F., Romagnoli, D., Zona, S., Targher, G., Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World Journal of Gastroenterology 22:44 (2016), 9674–9693.
13. Lovre, D., Htun, W., Carrion, C., Fonseca, V.A., What are we learning from the FDA-mandated cardiovascular outcome studies for new pharmacological antidiabetic agents?. Current Diabetes Reports, 16(10), 2016, 94.
14. Mende, C.W., Diabetes and kidney disease: The role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Current Medical Research and Opinion 15 (2016), 1–37 (Epub ahead of print).
15. Musso, G., Cassader, M., Rosina, F., Gambino, R., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomized trials. Diabetologia 55:4 (2012), 885–904.
16. Saponaro, C., Gaggini, M., Gastaldelli, A., Nonalcoholic fatty liver disease and type 2 diabetes: Common pathophysiologic mechanisms. Current Diabetes Reports, 15(6), 2015, 607.
17. Smits, M.M., Tonneijck, L., Muskiet, M.H., Kramer, M.H., Pouwels, P.J., Pieters-van den Bos, I.C.,.. Cahen, D.L., Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: A randomised placebo-controlled trial. Diabetologia 59:12 (2016), 2588–2593.
18. Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S.,.. Zhu, D., Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized and non-randomized studies. Diabetes/Metabolism Research and Reviews 32:2 (2016), 200–216.
19. Targher, G., Chonchol, M., Pichiri, I., Zoppini, G., Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: Just a coincidence?. Journal of Endocrinological Investigation 34:7 (2011), 544–551.
20. Zhao, C.C., Wang, A.P., Li, L.X., Li, T.T., Chen, M.Y., Zhu, Y.,.. Jia, W.P., Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. Journal of Diabetes and its Complications 30:6 (2016), 1074–1080.